News
PHVS
34.84
-0.20%
-0.07
Weekly Report: what happened at PHVS last week (0803-0807)?
Weekly Report · 16h ago
Can Pharvaris (PHVS) Turn AAE-C1INH Patient Insights Into a Lasting Clinical Advantage?
Simply Wall St · 1d ago
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
Seeking Alpha · 6d ago
Morgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)
TipRanks · 08/03 12:45
Weekly Report: what happened at PHVS last week (0727-0731)?
Weekly Report · 08/03 09:03
Weekly Report: what happened at PHVS last week (0720-0724)?
Weekly Report · 07/27 09:03
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
The Motley Fool · 07/24 11:21
Pharvaris announces publication of review article on bradykinin
TipRanks · 07/22 10:55
Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology
Benzinga · 07/22 10:53
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Barchart · 07/22 05:50
Pharvaris (PHVS) Could Be 92% Undervalued On FDA NDA Acceptance
Simply Wall St · 07/20 15:25
Weekly Report: what happened at PHVS last week (0713-0717)?
Weekly Report · 07/20 09:03
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Seeking Alpha · 07/19 19:10
Did FDA’s NDA Acceptance for Deucrictibant Just Shift Pharvaris' (PHVS) Hereditary Angioedema Narrative?
Simply Wall St · 07/16 12:30
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
TipRanks · 07/15 13:35
Pharvaris Price Target Announced at $55.00/Share by Wells Fargo
Dow Jones · 07/15 11:12
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55
Benzinga · 07/15 11:03
Pharvaris initiated with an Overweight at Wells Fargo
TipRanks · 07/15 09:35
Weekly Report: what happened at PHVS last week (0706-0710)?
Weekly Report · 07/13 09:03
How Investors May Respond To Pharvaris (PHVS) FDA Acceptance Of Deucrictibant NDA For HAE Attacks
Simply Wall St · 07/08 15:40
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.